Physician profile
Christina A Robins
NPI 1629184668
$26,541.23
in general payments reported to CMS, 2019-2025
86 companies · $3,471 in 2025
The $3,471 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,927 · 2020: $3,165 · 2021: $3,885 · 2022: $5,194 · 2023: $4,020 · 2024: $3,880 · 2025: $3,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $20.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,350.00 |
| Education | $20.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,558.25 | 2019-2025 | Ubrelvy, Vraylar, Botox |
| Novo Nordisk INC | $1,981.04 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Antares Pharma, INC. | $1,282.04 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Optinose US, INC. | $1,241.34 | 2019-2023 | |
| Lilly USA, LLC | $1,067.91 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,031.70 | 2019-2025 | Xifaxan, Trulance, Ibschek |
| Merz North America, INC. | $848.33 | 2019-2021 | |
| Aytu Biopharma, INC. | $836.39 | 2019-2021 | |
| Bausch Health US, LLC | $824.44 | 2019-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, Lp | $754.94 | 2019-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Amgen INC. | $720.89 | 2020-2025 | Repatha, Otezla, Repatha |
| Corium, LLC | $622.32 | 2021-2025 | Azstarys |
| Allergan, INC. | $617.40 | 2019-2022 | |
| Axsome Therapeutics, INC. | $553.42 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Tris Pharma INC | $518.02 | 2022-2025 | Dyanavel Xr |
Show all 86 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Robins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.